Introduction
Canine parvovirus (CPV, the genus Parvovirus, the family Parvoviridae), an extremely virulent and contagious virus aff ecting dogs, wolves, foxes and other canines, causes most threatening disease to puppies between the time of weaning and six months of age. It causes severe acute leukopenia and enteritis in young and adult dogs, leading to death by dehydration and shock. Conventional vaccines against CPV include inactivated and modifi ed live virus vaccines (SmithCarr et al., 1997; Martella et al., 2005) . Inactivated vaccine requires high dose of antigen per immunization and adjuvant and on the other hand, modifi ed live virus is usually excreted aft er vaccination and not recommended during pregnancy.
To overcome these problems, attempts were made to develop other CPV vaccines including a recombinant vaccine utilizing baculovirus expression system, a synthetic peptide vaccine and CPV DNA vaccine (Turiso et al., 1992; Casal et al., 1995; Gupta et al., 2005; Patial et al., 2007) .
DNA vaccination has been proven as a major breakthrough in the development of novel immunization strategy to elicit immunity against a series of infectious agents (Dhamma et al., 2008, for review) . Although, DNA vaccination induces robust immune responses in mice, less successful in large animals mainly due to high doses of plasmid DNA required to induce suffi cient immunity and improper delivery of plasmid DNA to immune cells (MacGregor et al., 1998; Babiuk et al., 2003) . To overcome these limitations, the alphavirus replicon-based self-amplifying and self-limiting expression system has been developed and used to enhance antigen expression and improve DNA vaccination (Xiong et al., 1989; Herweijer et al., 1995; Hariharan et al., 1998; Berglund et al., 1998; Miller et al., 2008; Saxena et al., 2008; Anraku et al., 2002 Anraku et al., , 2008 . For delivery of plasmid DNA directly to cytoplasm of antigen-presenting cells, a variety of Grampositive and Gram-negative bacteria, including, Salmonella, Shigella and E. coli have been used successfully as carriers for effi cient delivery of either DNA vaccine constructs or vaccine antigens (Liljeqvist and Stahl, 1999; Gentschev et al., 2001; Schoen et al., 2004 for review) and for vaccination of model animals against a variety of infectious diseases of both bacterial and viral origin, including human immunodefi ciency virus (HIV, Karpenko et al., 2004) , hepatitis B virus (HBV, Patrick et al., 2001) , Newcastle disease virus (NDV, Fang et al., 2003) , and infectious bursal disease virus (IBDV, Li et al., 2006; Mahmood et al., 2007) . Th e enteropathogenic bacteria evaluated as DNA vaccine carriers are either extracellular pathogens, such as E. coli (Giacalone et al., 2007; Mahmood et al., 2007) and Yersinia spp. or intraphagosomal pathogens like Salmonella spp. (Li et al., 2006; Qu et al., 2008; Yang et al., 2009 Yang et al., , 2010 or intracytosolic pathogens, like, Listeria monocytogenes and Shigella spp. (Schoen et al., 2004) .
In the present study, the potential of Sindbis virus replicon-based DNA vaccine has been investigated by delivering the vaccine orally by non-pathogenic E. coli DH5α to induce immune responses against CPV in dogs. Th e induced CPVspecifi c humoral and cellular immune responses were compared with responses developed with commercial vaccine.
Materials and Methods
Virus and cells. CPV type 2b adapted to Madin Darby canine kidney (MDCK) cells was used in virus neutralization (VN) test and in preparation of inactivated purifi ed antigen. MDCK cells were procured from National Centre for Cell Science (NCCS, Pune, India) and grown at 37°C under 5% CO 2 in Dulbecco΄s modifi ed minimum essential medium (DMEM, Hyclone), supplemented with 10% fetal calf serum (FCS, Hyclone) and 50 μg/ml gentamicin.
DNA vaccine. To construct Sindbis virus replicon-based CPV DNA vaccine (pAlpha-CPV-VP2), the DNA fragment containing full length VP2 gene was obtained by digesting pTargeT-CPV-VP2 (Gupta et al., 2005) with NheI and SmaI restriction endonucleases and ligated into XbaI and StuI sites in Sindbis virus replicon-based DNA vaccine vector, pAlpha (Saxena et al., 2008) .
Commercial vaccine. Inactivated vaccine, Megavac-P Inact (Indian Immunologicals, India) was used as commercial vaccine.
E. coli transformed with DNA vaccine. Th e E. coli DH5α transformed with pAlpha-CPV-VP2 was grown on LB agar plates containing kanamycin for 10 passages. Th e stability of the plasmids was evaluated by plasmid isolation and restriction enzyme analysis. Safety of transformed E. coli DH5α as vaccine vehicle was analyzed by inoculating orally 10 times higher dose (10 10 CFU per dog) of bacterial culture to a group of three dogs. Th e dogs were observed for any symptoms of reaction or abnormality during the period of experimentation. For large scale preparation of E. coli carrying vaccine plasmid, bacterial culture carrying vaccine plasmid was grown overnight with shaking. Bacterial cells were recovered by centrifugation at 5,000 rpm for 10 mins and the pellet was resuspended in PBS (pH 7.2). Th e bacterial colony forming units (CFUs) per ml were determined by plating serial dilutions of resuspended culture on LB agar plates. Th e concentration was adjusted to 10 9 CFU per ml and used as vaccine.
Vaccination of dogs. Two groups of seronegative (with VN titer <1:10) apparently healthy dogs (each n = 3) aged between four and eight weeks, were orally inoculated by 1 ml of E. coli containing pAlpha-CPV-VP2 in concentration 10 9 CFU or by empty vector. One seronegative group (n = 3) of dogs was immunized intramuscularly with 1 ml (one dose) of commercial vaccine. One group (n = 3) of dogs received PBS and kept as negative control group. All groups of dogs received booster on day 21 post-immunization. Th e serum samples were collected from immunized dogs on day 0, 21, 30, and 40 for determination of CPV-specifi c IgG and VN titer.
ELISA. To evaluate IgG antibody response against CPV in immunized dogs, sera from all dogs were analyzed in ELISA following the method described earlier using inactivated CPV as ELISA coating antigen (Patial et al., 2007) . For end point titer determination, a positive was scored for any sample with an absorbance more than absorbance from healthy dogs sera with two times the standard deviation. Th e ELISA titers were defi ned as the reciprocal of the highest serum dilution positive in ELISA and presented as GMT±SEM.
Virus neutralization test. To determine the protective status among the vaccinated groups, sera from all dogs were analyzed in VN test following the method described earlier (Gupta et al., 2005) . Th e VN titer was calculated as the reciprocal of the highest serum dilution of sera that neutralized 100 TCID 50 of CPV and presented as GMT±SEM. A VN titer 1:20 and above was considered as protective as described earlier (Smith-Carr et al., 1997; Pollock and Carmichael, 1982a,b; www.veterinarypartner.com) .
Lymphocyte proliferation test. Th e CPV-specifi c cell mediated immune (CMI) response in immunized dogs was determined by lymphocyte proliferation test and immunophenotyping of eff ector cells in peripheral blood mononuclear cells (PBMCs) from all the immunized dogs on day 40 aft er immunization. Th e lymphocyte proliferation test was performed using MTT dye in PBMCs isolated from each dog following the method described earlier (Saxena et al., 2008) aft er stimulation with inactivated CPV antigen along with positive controls, concavalin A (Con A) and phytohemagglutinin (PHA). Stimulation indices (SI) were calculated as ratio of absorbance of stimulated cells to absorbance of unstimulated cells.
Immunophenotyping. For immunophenotyping of effector (CD4 + and CD8 + ) cells, the PBMCs were stimulated in vitro with inactivated CPV antigen for 48 hrs. Th e cells were stained with FITC, RPE and ALEXA 647-conjugated cocktail of monoclonal antibodies specifi c for cell surface antigens CD3, CD4, and CD8 (Serotec), respectively following the method described earlier (Saxena et al., 2008) . Th e numbers of CD3 + CD4
+ and CD3 + CD8 + cells from duplicate samples collected from all dogs were acquired per 10,000 cells per sample using BD FACS Calibur fl owcytometer (BD Biosciences) and acquired data were analyzed using BD CellQuest program (BD Biosciences). Fold increase in eff ector cell population on stimulation with inactivated purifi ed CPV antigen over unstimulated cells was calculated. Statistical analysis. Th e signifi cance for induction of CPVspecifi c responses induced in lymphocyte proliferation test, IgG ELISA, and VN titers was analyzed using two-way ANOVA using GraphPad Prism version 4.03 soft ware (GraphPad). All data were presented as the GMT±SEM.
Results and Discussion

Antibody responses to DNA vaccine
Th e aim of this study was to assess the effi cacy of oral vaccination in dogs with non-pathogenic E. coli DH5α delivering a Sindbis virus replicon-based CPV DNA vaccine. Th e oral vaccination was selected with advantages of bacterial delivery of DNA encoding antigens to both mucosal and systemic immune systems, cost effi ciency and acceptability of oral and other forms of mucosal delivery. To assess the immunogenicity of DNA vaccine, CPV-specifi c humoral IgG immune response in immunized dogs was measured at diff erent time intervals and compared with dogs immunized with commercial vaccine. CPV-specifi c seroconversion was observed in all vaccinated dogs. Th e DNA vaccine demonstrated signifi cantly high IgG ELISA titer on day 21 post-immunization which increased aft er booster dose (Fig. 1) . Th e commercial vaccine also showed seroconversion, however, it was not signifi cant on day 21 post-immunization but increased to signifi cant level aft er booster dose. Th ere was no or non-signifi cant seroconversion in dogs in control groups.
To assess the protective effi cacy of CPV vaccines, the sera collected from all immunized and control dogs were analyzed for presence of VN antibody. Th e DNA vaccine demonstrated VN titer (>32) on day 21 post-immunization which crossed the protective status (VN titer ≥20). As described earlier, a VN titer >1:20 indicates protective status against CPV (Pollock and Carmichael, 1982a,b; Smith-Carr et al., 1997; www.veterinarypartner.com) . Further, in this study, an anamestic response was seen in both CPV vaccine immunized groups aft er the booster dose with VN titer above the protective threshold (Fig. 2) . Th ere was no or non-signifi cant seroconversion (VN titer <4) seen in dogs immunized with either empty vector or healthy control groups. 
CMI responses to DNA vaccine
Th e CMI response elicited by DNA vaccine was analyzed in isolated PBMCs aft er in vitro stimulation with inactivated CPV antigen and compared with commercial vaccine. As shown in Fig. 3 , the CPV-specifi c lymphocyte proliferative response with DNA vaccine or commercial vaccine was signifi cantly high. Th ere were no CPV-specifi c proliferative responses detected in dogs receiving empty vector or PBS (negative control). Th e proliferative responses of PBMCs from all dogs (immunized and control) with non-specifi c stimulator (Con A or PHA) confi rmed that the cells were healthy and competent to proliferate.
On phenotypic characterization of lymphocytes it was found that both (CD4 + and CD8 + ) eff ector cells were stimulated with DNA vaccine and commercial vaccine (Fig. 4) . On in vitro stimulation with inactivated CPV antigen, there was more than 2-fold increase in both (CD4 + and CD8 + ) lymphocytes in dogs vaccinated with DNA vaccine (Fig. 5) indicating presence of sensitized lymphocytes in DNA vaccine immunized dogs. It has been reported in earlier studies Increase in CD3+CD4+ and CD3+CD8+ lymphocytes in response to CPV vaccines that replicon-based DNA vaccine against other diseases induced CMI response through induction of apoptosis (Albert et al., 1998; Kohno et al., 1998; Leitner et al., 2000; Saxena et al., 2008) and generation of dsRNA intermediates during the alphavirus-replicon replication which served as T-cell adjuvant to encoded antigen (Leitner et al., 1999; Saxena et al., 2008) . In this study, the signifi cantly high CPV-specifi c CMI response compared to commercial vaccine group may be attributed to the apoptosis and/or the dsRNA adjuvant eff ects. Th is study reports the successful oral vaccination by E. coli DH5 delivering replicon-based CPV DNA vaccine for eliciting suffi cient levels of antibody and cellular immune responses specifi c to CPV. Th is method of immunization is convenient and cost-eff ective. Taken together, oral DNA vaccination may be an eff ective alternative strategy for vaccination of the dogs and can be considered as a promising approach for mass vaccination of dogs.
